A therapeutic galcanezumab, initially identified as LY2951742, represents the critical advance in migraine management. Its chemical structure is that of a humanized monoclonal protein, specifically targeting the https://socialrus.com/story24728235/galcanezumab-a-deep-dive-into-ly2951742-and-its-chemical-identity